866-997-4948(US-Canada Toll Free)

Paclitaxel (Ovarian Cancer) Analysis and Forecasts to 2020

Published By :

GlobalData

Published Date : Oct 2011

Category :

Ovarian Cancer

No. of Pages : 35 Pages

 

GlobalDatas pharmaceuticals report, "Paclitaxel (Ovarian Cancer) - Analysis and Forecasts to 2020 provides Paclitaxel sales forecasts for the US, EU and Japan. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2002-2020). The report also includes information on Ovarian Cancer market. This report is built using data and information sourced from GlobalDatas proprietary databases, primary and secondary research using Companys corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by GlobalData's team of industry experts.

 

Scope

 

  • Therapy area profile including patient population for the US, EU and Japan (seven major markets)
  • Analysis and review of Paclitaxel including sales data 
  • Qualitative and quantitative assessment of market space
  • Analysis of the trends, drivers and restraints shaping and defining the markets
  • In-depth analysis of Paclitaxel including efficacy, safety, pricing, competition and other details which influence its sales potential
  • Detailed sales forecast for 2002-2020 for Paclitaxel in the seven major markets

 

Reasons to buy

 

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of competition by understanding the changing competitive landscape
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of the drugs performance 
  • Examine the historical sales performance of a drug in seven major markets
  • Obtain sales forecast for currently marketed/pipeline drug for 2011-2020 for all seven major markets

Table of Contents

 

1 Table of Contents 2
1.1 List of Tables 3
1.2 List of Figures 3


2 Introduction 4
2.1 Ovarian Cancer 4
2.2 Ovarian Cancer Market 4
2.3 Epidemiology 4
2.4 Etiology 6
2.4.1 Age 6
2.4.2 Inherited Gene Mutations 6
2.4.3 A Previous Cancer Diagnosis 6
2.4.4 Early Menstruation or Late Menopause 7
2.4.5 Family History of Ovarian Cancer 7
2.5 GlobalData Report Guidance 7


3 Ovarian Cancer: Market Characterization 8
3.1 Ovarian Cancer Market 8
3.2 Ovarian Cancer Market Forecasts and CAGR 8
3.3 Drivers for Ovarian Cancer Market 9
3.3.1 High Incidence 9
3.3.2 High Mortality Rate 10
3.3.3 Increased Use of Chemotherapy in Ovarian Cancer 11
3.3.4 Emergence of Targeted Drugs 11
3.3.5 Recurrence of Tumor 11
3.3.6 Low Initial Diagnosis Rate 11


4 Tumor-Node-Metastases (TNM) Classification of Ovarian Cancer 12


5 Paclitaxel 15
5.1 Introduction 15
5.2 Mechanism of Action 15
5.3 Clinical Studies 15
5.3.1 First Line of Treatment of Advanced Ovarian Cancer 15
5.3.2 Second Line of Treatment of Advanced Ovarian Cancer 16
5.4 Approval History of Taxol 17
5.5 Factors Affecting Sales 17
5.5.1 Patent Expiry of Taxol 17
5.5.2 Increase in generic competition 17
5.5.3 Highest Efficacy of paclitaxel in Combination with cisplatin for the First Line Treatment 17
5.5.4 Better efficacy of paclitaxel in combination with Avastin for advanced ovarian cancer. 17
5.6 Drug Evaluation 18
5.6.1 Drug Risk Benefit Score 18
5.7 Sales Forecasts 20
5.7.1 Target Patient Pool of Paclitaxel 20
5.7.2 Dosing 20
5.7.3 Market Penetration 21
5.7.4 Annual Cost of Therapy 21
5.7.5 Sales Projections of Paclitaxel 22


6 Ovarian Cancer Market: Appendix 31
6.1 Market Definitions 31
6.2 List of Abbreviations 31
6.3 Research Methodology 31
6.3.1 Coverage 31
6.3.2 Secondary Research 32
6.3.3 Forecasting 32
6.3.4 Number of Patients Approved to take the Drug 32
6.3.5 Net Penetration of Drug 34
6.3.6 Net Annual Dosing 34
6.3.7 Annual Cost of Therapy 34
6.3.8 Primary Research 34
6.3.9 Expert Panels 35
6.4 Contact Us 35
6.5 Disclaimer 35
6.6 Sources 35

List of Table


Table 1: Ovarian Cancer, Incidences and Mortality, 20082030 6
Table 2: Ovarian Cancer, Global, Market Size Forecasts ($m), 20092020 8
Table 3: Detailed TNM Classification 13
Table 4: Phase III Trial Results of Taxol, First Line, Intergroup Study 16
Table 5: Phase III Trial Results of Taxol, First Line, Gynaecological Oncology Group Study 16
Table 6: Phase III Trial Results of Taxol, Second Line, Ovarian Cancer 16
Table 7: Approval of Taxol by Indication 17
Table 8: Drug Risk Benefit Score of Taxol as First Line Treatment 18
Table 9: Annual Cost of Therapy of Paclitaxel, 2011 21
Table 10: Paclitaxel, Ovarian Cancer, Global, Sales Estimates ($m), 20022020 22
Table 11: Paclitaxel, Ovarian Cancer, The US, Sales Estimates ($m), 20022020 23
Table 12: Paclitaxel, Ovarian Cancer, The UK, Sales Estimates ($m), 20022020 24
Table 13 Paclitaxel, Ovarian Cancer, France, Sales Estimates ($m), 20022020 25
Table 14: Paclitaxel, Ovarian Cancer, Germany, Sales Estimates ($m), 20022020 26
Table 15: Paclitaxel, Ovarian Cancer, Italy, Sales Estimates ($m), 20022020 27
Table 16: Paclitaxel, Ovarian Cancer, Spain, Sales Estimates ($m), 20022020 28
Table 17: Paclitaxel, Ovarian Cancer, Japan, Sales Estimates ($m), 20022020 29

List of Chart


Figure 1: Distribution by Incidence and Mortality, Most Commonly Diagnosed Cancers, Worldwide, 2010 5
Figure 2: Ovarian Cancer, Global, Market Size Forecasts ($m), 20092020 8
Figure 3: Ovarian Cancer, Worldwide, Incidence (in million), 2008-2030 9
Figure 4: Oncology, Worldwide, Incidence (in million), 2008-2030 10
Figure 5: Ovarian Cancer, Worldwide, Mortality (in million), 2008-2030 10
Figure 6: Broad Classification of Ovarian Cancer 12
Figure 7: Classification of Ovarian Cancer 14
Figure 8: Drug Model Diagram of Paclitaxel in the US, EU and Japan 20
Figure 9: Paclitaxel, Ovarian Cancer, Global, Sales Estimates ($m), 20022020 22
Figure 10: Paclitaxel, Ovarian Cancer, The US, Sales Estimates ($m), 20022020 23
Figure 11: Paclitaxel, Ovarian Cancer, The UK, Sales Estimates ($m), 20022020 24
Figure 12: Paclitaxel, Ovarian Cancer, France, Sales Estimates ($m), 20022020 25
Figure 13: Paclitaxel, Ovarian Cancer, Germany, Sales Estimates ($m), 20022020 26
Figure 14: Paclitaxel, Ovarian Cancer, Italy, Sales Estimates ($m), 20022020 27
Figure 15: Paclitaxel, Ovarian Cancer, Spain, Sales Estimates ($m), 20022020 28
Figure 16: Paclitaxel, Ovarian Cancer, Japan, Sales Estimates ($m), 2002-2020 29
Figure 17: Paclitaxel, Ovarian Cancer, Global, Sales Distribution (%), 2015 30
Figure 18: Drug Model Diagram 33
Figure 19: Patients Approved for the Drug 33

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *